Landos Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	10.73	14.88	15.25	5.34	1.48	1.14
Research & Development	12	25.68	41.56	25.34	11.81	6.8
Operating Expenses	22.73	40.56	56.82	30.68	13.29	7.94
Operating Income	-22.73	-40.56	-56.82	-30.68	-13.29	-7.94
Interest Expense / Income	0	0	0	0	0.3	0
Other Expense / Income	-0.79	-1.29	-18.39	-0.53	-0.13	-1.9
Pretax Income	-21.94	-39.28	-38.42	-30.14	-13.47	-6.04
Net Income	-21.94	-39.28	-38.42	-30.14	-13.47	-6.04
Shares Outstanding (Basic)	6	4	4	1	1	1
Shares Outstanding (Diluted)	6	4	4	1	1	1
Shares Change	55.90%	7.18%	207.16%	7.32%	10.74%	-
EPS (Basic)	-3.50	-9.76	-10.20	-24.70	-11.80	-5.90
EPS (Diluted)	-3.50	-9.76	-10.20	-24.70	-11.80	-5.90
Free Cash Flow	-20.48	-45.54	-27.5	-23.14	-10.03	-6.94
Free Cash Flow Per Share	-3.26	-11.31	-7.32	-18.93	-8.80	-6.74
EBITDA	-21.94	-38.7	-38.23	-30.01	-13.06	-5.96
Depreciation & Amortization	0	0.58	0.2	0.14	0.1	0.08
EBIT	-21.94	-39.28	-38.42	-30.14	-13.16	-6.04

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).